Rna viruses expressing il-12 for immunovirotherapy

ABSTRACT

The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a Continuation of U.S. application Ser. No.15/441,545, filed Feb. 24, 2017; which claims the benefit of U.S.Provisional Application No. 62/299,788, filed Feb. 25, 2016, whichapplication is incorporated herein by reference.

FIELD OF THE INVENTION

This invention relates to biotechnology, including modified viruses,especially for the treatment or prevention of a human disease.

BACKGROUND

Interleukin 12 (IL-12) is a heterodimeric polypeptide interleukinconsisting of two subunits, p35 and p40, encoded by two separate genes,IL-12A and IL-12B, respectively. IL-12 is produced in response to immunestimuli by dendritic cells, macrophages, neutrophils, and by humanB-lymphoblastoid cells, and has been known as an important stimulator ofimmune cell activity, in particular of T cells and natural killer cells,which are, among other effects, stimulated to secrete IFN-γ by IL-12.IFN-γ, in turn, is known to stimulate expression of immune checkpointblockade proteins on non-immune cells, e.g. of PD-L1, a mechanism usedby cancer cells to evade the immune system (Abiko et al. (2015), Britishjournal of cancer 112(9): 1501; Quetglas et al. (2015) Cancer Research75(15 Supplement): 281). Due to the known immunostimulatory effects ofIL-12, it was attempted to use a recombinant measles virus expressingboth subunits of IL-12 as a vaccine to improve immune response againstmeasles virus. However, it was found that the transgene had adetrimental effect on the neutralizing antibody response and thatlymphoproliferative responses were not improved (Hoffman et al. (2003),J Infect Dis 188:1553).

Oncolytic viruses (OV) which replicate selectively in tumor cells are anemerging modality of cancer treatment. Aside from direct cytopathiceffects and lysis of tumor cells, interactions of OV with the immunesystem can trigger systemic anti-tumor immunity. OV have been modifiedto express immunomodulatory transgenes to further enhance these effects(Melcher et al., Mol Ther. 2011, 19: 1008-1016). The vaccinia virusJX-594 and herpesvirus talimogene laherpavec (TVEC), both harboringGM-CSF, have shown promising results in clinical phase II and III trials(Heo et al., Nat Med. 2013,19: 329-336 and Andtbacka et al. J ClinOncol. 2013, 31, suppl; abstr LBA9008).

RNA viruses, in particular members of the family Paramyxoviridae like,e.g. measles virus (MV), have also shown potential use in oncolysis.Viruses of the family Paramyxoviridae are negative-sense single-strandedRNA viruses and include human pathogens like, e.g. human parainfluenzaviruses, mumps virus, human respiratory syncytial virus, and measlesvirus. From wild type measles virus, several non-pathogenic strains,including a vaccine strain, have been derived, which have been shown toremain oncolytic. The measles virus vaccine strain has been developed asa vector platform to target multiple tumor entities and several clinicaltrials are ongoing (Russell et al., Nat Biotechnol. 2012, 30: 658-670).Recently, the capacity of oncolytic MV encoding GM-CSF to support theinduction of a specific anti-tumor immune response in terms of a tumorvaccination effect was demonstrated (Grossardt et al. Hum Gene Ther.2013, 24: 644-654.).

There is, however, still a need in the art for improved cancertherapies, in particular for improved oncolytic virus therapies. It istherefore an objective of the present invention to provide an improvedoncolytic virus, which fully or partially avoids the short-comings ofknown oncolytic viruses.

SUMMARY OF THE INVENTION

The present invention relates to a recombinant virus of the familyParamyxoviridae, comprising at least one expressible polynucleotideencoding an IL-12 polypeptide, wherein said IL-12 polypeptide is anIL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40subunit of an IL-12; to a polynucleotide encoding the same, and to a kitcomprising the same. Moreover, the present invention relates to a methodfor treating cancer in a subject afflicted with cancer, comprisingcontacting said subject with a recombinant virus of the familyParamyxoviridae of the invention, and, thereby, treating cancer in asubject afflicted with cancer.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: One step growth curves in Vero-αHis (A) and MC38cea (B) cells:Cells were transduced with MeVac encoding the respective transgenes atMOI=3. Cell suspensions were collected by scraping in the culture mediumand titre determined at the depicted time points.

FIG. 2: Cytotoxic effect in the target MC8cea cells: Cells weretransduced with MeVac encoding the respective transgenes at MOI=5 andcell viability was determined by XTT assay at the depicted time points.Mean results of triplicate infections per time point with standarderrors of the mean (not visible for some data points) are shown.

FIG. 3: Expression of MeVac encoded immunomodulators in MC38cea cells.MC38cea cells were transduced with MeVac encoding the respectiveimmunomodulators and eGFP or IgG1-Fc as control vectors at MOI=3.Supernatant samples were collected at the depicted time points andtransgene expression detected by ELISA. Unspecific binding wascontrolled by IgG1-Fc (upper panels) or eGFP (lower panels) supernatantsand subtracted from the specific measurements. In case of mIP-10 anincrease of the signal was observed in the eGFP controls which was notsubtracted from the specific measurements and is depicted accordingly.

FIG. 4: MeVac encoded anti-PD-L1 binding to MC38cea cells. MC38cea cellswere incubated with supernatant from Vero-αHis infected with MeVacencoding anti-PD-L1 or IgG1-Fc. For detection of bound anti-PD-L1, cellswere stained with primary Ab specific for HA tag and secondary Abcoupled to PE. DAPI staining was used to exclude dead cells and sampleswere analyzed by flow cytometry. (A) Overlay histogram for PE of DAPI-MC38cea populations from one of three independent experiments is shownon panel (B). (B)Average median fluorescence intensity (MFI) of PE forDAPI-populations with standard error of the means from the threeindependent experiments is shown on the left panel.

FIG. 5: Functionality of MeVac encoded immunomodulators. (A) MC38ceacells were treated with supernatants from Vero-αHis cells infected withMeVac encoding the respective immunomodulators and cocultured in ratio2:1 with murine splenocytes in the presence of PMA and ionomycin in96-well plate. After 24 h the supernatants were collected and IFN-γconcentration measured by ELISA. Relative activation corresponds toratio of the optical density (absorbance at 450 nm minus 570 nm) of therespective samples to activated splenocytes. Data for one of threeindependent experiments are shown; (B) splenocytes were stimulated withrecombinant murine IL-2 and cultivated in the presence of medium fromVero-αHis infected with MeVac encoding FmIL-12 or eGFP. After 48 h thesupernatants were collected and IFN-γ concentration measured by ELISA.Mean results with standard error of the mean of triplicate splenocytecultures per FmIL-12 concentration are shown. IFN-γ concentration in theeGFP controls was close to background.

FIG. 6: Therapeutic efficacy of immunomodulatory MeVac in vivo: Breakingimmunosuppression: MC38cea cells were implanted subcutaneously (s.c.)into the right flank of C57BL/6J mice (6-9 animals per group). Whentumors reached an average volume of 50 mm3 mice received intratumoralinjections with 1×10⁶ cell infectious units (ciu) with the respectiveviruses on four consecutive days in 100 Tumor volume was determinedevery third day and mice were sacrificed when tumor volumes exceeded1500mm³ or when ulceration occurred.

FIG. 7: Therapeutic efficacy of immunomodulatory MeVac in vivo:Activating DCs and effector cells: Therapeutic. MC38cea cells wereimplanted subcutaneously (s.c.) into the right flank of C57BL/6J mice(6-9 animals per group). When tumors reached an average volume of 50 mm3mice received intratumoral injections with 5×10⁵ ciu with the respectiveviruses on five consecutive days in 100 μl. Tumor volume was determinedevery third day and mice were sacrificed when tumor volumes exceeded1500 mm³ or when ulceration occurred.

FIG. 8: Rechallenge of long term survivors with MC38cea. Miceexperiencing complete tumor remission in the experiments identifying themost effective MeVac vectors and were rechallenged with MC38cea cells 3to 6 months after the initinal tumor cell implantation. Eight I miceserved as a control group. 1×105 MC38cea cells were implantedsubcutaneously (s.c.) in the left flank of the mice. Tumor engraftmentrates were monitored.

FIG. 9: Comparison of therapeutic efficacy of MeVac encoding FmIL-12 andanti-PD-L1. MC38cea cells were implanted subcutaneously (s.c.) into theright flank of C57BL/6J mice (10 animals per group). When tumors reachedan average volume of 50 mm3 mice received intratumoral injections with1×106 ciu with the respective viruses on four consecutive days in 100μl. Tumor volume was determined every third day and mice were sacrificedwhen tumor volumes exceeded 1500 mm3 or when ulceration occurred.

FIG. 10: Rechallenge of long term survivors from the experimentcomparing efficacy of FmIL-12 and anti-PD-L1 encoding vectors withMC38cea. Mice were rechallenged with MC38cea cells ca. 6 months afterthe initinal tumor cell implantation. Ten I mice served as a controlgroup. 1×105 MC38cea cells were implanted subcutaneously (s.c.) in theleft flank of the mice. Tumor engraftment rates were monitored.

FIG. 11: IFN-γ memory recall in murine splenocytes from miceexperiencing complete tumor remissions in MeVac FmIL-12 versus MeVacanti-PD-L1 efficacy experiment. Anti-tumor: Freshly isolated splenocytesfrom mice treated with MeVac encoding the respective immunomodulators ornaïve mice were stimulated with recombinant murine IL-2 and cocultivatedwith MC38cea (A) or MC38 (B) and B16 (B) tumor cells or irrelevant humancell lysate (DLD-1). After 48 h of cultivation cell culture medium wascollected and IFN-γ concentration was measured by ELISA. IFN-γconcentrations in the individual cocultures with median in the group (A)or average concentration from two replicate measurements with standarderror of the mean (SEM) are shown (B).

FIG. 12: IFN-γ memory recall in murine splenocytes from miceexperiencing complete tumor remissions in MeVac FmIL-12 versus MeVacanti-PD-L1 efficacy experiment: Anti-MeVac: Freshly isolated splenocytesfrom mice treated with MeVac encoding the respective immunomodulators ornaïve mice were stimulated with recombinant murine IL-2 and cocultivatedwith MeVac (A) or as controls with an irrelevant human cell lysate(DLD-1) (B) or as a negative control splenocytes were cultivated alone.After 48 h of cultivation cell culture medium was collected and IFN-γconcentration was measured by ELISA. IFN-γ concentrations in theindividual cocultures with median in the group (A) or averageconcentration from two replicate measurements with standard error of themean (SEM) are shown (B).

FIG. 13: Comparison of therapeutic efficacy of combination of MeVacencoding Fm-IL-12 and anti-PD-L1 with either vector in combination witha control vector encoding IgG1-Fc. MC38cea cells were implantedsubcutaneously (s.c.) into the right flank of C57BL/6J mice (8-10animals per group). When tumors reached an average volume of 50 mm3 micereceived intratumoral injections with 1×106 ciu with the respectiveviruses on four consecutive days in 100 Tumor volume was determinedevery third day and mice were sacrificed when tumor volumes exceeded1500 mm3 or when ulceration occurred.

FIG. 14: Rechallenge of long term survivors from the experimentcomparing efficacy of combination of MeVac encoding Fm-IL-12 andanti-PD-L1 with either vector in combination with a control vectorencoding IgG1-Fc. Mice were rechallenged with MC38cea cells ca. 5 monthsafter the initinal tumor cell implantation. Ten I mice served as acontrol group. 1×105 MC38cea cells were implanted subcutaneously (s.c.)in the left flank of the mice. Tumor engraftment rates were monitored.

FIG. 15: IFN-γ memory recall in murine splenocytes from miceexperiencing complete tumor remissions in MeVac FmIL-12 and MeVacanti-PD-L1 combination experiment: Anti-tumor: Freshly isolatedsplenocytes from mice treated with MeVac encoding the respectiveimmunomodulators or naïve mice were stimulated with recombinant murineIL-2 and cocultivated with MC38cea (A), MC38 (B) or B16 (C) tumor cells.After 48 h of cultivation cell culture medium was collected and IFN-γconcentration was measured by ELISA. IFN-γ concentrations in theindividual cocultures with median in the group (A) or averageconcentration from two replicate measurements with standard error of themean (SEM) are shown (B).

FIG. 16: IFN-γ memory recall in murine splenocytes from miceexperiencing complete tumor remissions in MeVac FmIL-12 and MeVacanti-PD-L1 combination experiment: Anti-MeVac: Freshly isolatedsplenocytes from mice treated with MeVac encoding the respectiveimmunomodulators or naïve mice were stimulated with recombinant murineIL-2 and cocultivated with MeVac (A) or Vero-αHis lysate (B). After 48 hof cultivation cell culture medium was collected and IFN-γ concentrationwas measured by ELISA. IFN-γ concentrations in the individual cocultureswith median in the group (A) or average concentration from two replicatemeasurements with standard error of the mean (SEM) are shown (B).

FIG. 17: Comparison of therapeutic efficacy of combination of MeVacencoding Fm-IL-12 and anti-PD-L1 with either vector in combination witha control vector encoding IgG1-Fc. B16-CD20 cells were implantedsubcutaneously (s.c.) into the right flank of C57BL/6J mice (8-10animals per group). When tumors reached an average volume of 50 mm3 micereceived intratumoral injections with 1×106 ciu with the respectiveviruses on four consecutive days in 100 μl. Tumor volume was determinedevery third day and mice were sacrificed when tumor volumes exceeded1500 mm3 or when ulceration occurred.

FIG. 18: Schemes of the constructed recombinant MeVac genomes.Transgenes encoding different immunomodulators as well as eGFP andIgG1-Fc as controls were inserted in different positions of MeVacgenome. Murine IL-12 was inserted as a fusion protein consisting of p40and p35 protein subunits linked by a (Gly4Ser)3 linker (FmIL-12). MurineCD80 was inserted as a soluble form of the protein consisting of theextracellular part of the protein fused to a human IgG1-Fc (CD80-Fc).The MeVac H gene in the novel constructs was fully retargeted to humanCEA (hCEA) antigen by ablating attachment to the natural receptors,fusing the H protein to a single chain antibody (7cab) against the hCEAand including a six-histidine tag at the C terminus to allow specifictransduction of murine MC38cea cells via human CEA antigen and Vero-αHiscells via anti-His 7cab.

FIG. 19: Scheme of MeVac genomes encoding FmIL-12 or anti-PD-L1 orIgG1-Fc retargeted to human CD20. MeVac H gene was fully retargeted tohuman CD20 antigen by ablating attachment to the natural receptors,fusing the H protein to a single chain antibody (7cab) against the CD20and including a six-histidine tag at the C terminus to allow specifictransduction of murine melanoma B16-CD20 cells via human CD20 antigenand Vero-αHis cells via anti-His 7cab.

DETAILED DESCRIPTION OF THE INVENTION

Accordingly, the present invention relates to a recombinant virus of thefamily Paramyxoviridae, comprising an expressible polynucleotideencoding an IL-12 polypeptide, wherein said IL-12 polypeptide is anIL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40subunit of an IL-12.

As used in the following, the terms “have”, “comprise” or “include” orany arbitrary grammatical variations thereof are used in a non-exclusiveway. Thus, these terms may both refer to a situation in which, besidesthe feature introduced by these terms, no further features are presentin the entity described in this context and to a situation in which oneor more further features are present. As an example, the expressions “Ahas B”, “A comprises B” and “A includes B” may both refer to a situationin which, besides B, no other element is present in A (i.e. a situationin which a solely and exclusively consists of B) and to a situation inwhich, besides B, one or more further elements are present in entity A,such as element C, elements C and D or even further elements.

Further, as used in the following, the terms “preferably”, “morepreferably”, “most preferably”, “particularly”, “more particularly”,“specifically”, “more specifically” or similar terms are used inconjunction with optional features, without restricting alternativepossibilities. Thus, features introduced by these terms are optionalfeatures and are not intended to restrict the scope of the claims in anyway. The invention may, as the skilled person will recognize, beperformed by using alternative features. Similarly, features introducedby “in an embodiment of the invention” or similar expressions areintended to be optional features, without any restriction regardingalternative embodiments of the invention, without any restrictionsregarding the scope of the invention and without any restrictionregarding the possibility of combining the features introduced in suchway with other optional or non-optional features of the invention.Moreover, if not otherwise indicated, the term “about” relates to theindicated value with the commonly accepted technical precision in therelevant field, preferably relates to the indicated value ±20%.

The terms “virus” and “virus of the family Paramyxoviridae” are known tothe skilled person. Preferably, the virus of the family Paramyxoviridaeis a member of the genus Morbillivirus. More preferably, the virus ofthe family Paramyxoviridae is a measles virus (MV), still morepreferably an MV of strain Edmonston A or B, preferably B. Mostpreferably, the virus of the family Paramyxoviridae is an MV of vaccinestrain Schwarz/Moraten.

The term “recombinant virus”, as used herein, relates to a viruscomprising a genome modified by biotechnological means as compared toknown, naturally occurring, virus genomes. Preferably, the recombinantvirus is a virus comprising a genome modified as compared to naturallyoccurring virus genomes. Preferred biotechnological means for modifyinga viral genome are known to the skilled person and include any of themethods of molecular cloning, in particular recombinant DNA techniquesincluding, without limitation, cleavage of DNA by restriction enzymes,ligation of DNA, polymerase chain reaction (PCR), cloning of viralgenomes, and the like. It is understood by the skilled person thatviruses of the family Paramyxoviridae have a single-stranded (−)-RNA asa genome. Accordingly, the genome of the recombinant virus of thepresent invention, preferably, is obtained by cloning an expressionvector as described herein below comprising an expressible nucleotidesequence encoding said recombinant virus genome, followed by expressingsaid expressible nucleotide sequence encoding said recombinant virus ina permissive host cell. Alternatively, the recombinant virus genome mayalso be expressed in non-permissive host cells, e.g., preferably, fromrodents or other higher eukaryotes. Preferably, the recombinant virus ofthe present invention is a recombinant virus of the familyParamyxoviridae, more preferably a recombinant Morbillivirus, mostpreferably, a recombinant measles virus (MV). As will be understood bythe skilled person, the recombinant virus of he present invention maycomprises further modifications as compared to a naturally occurringvirus. Preferably, the recombinant virus comprises a polypeptidemediating a modified tropism and/or a polynucleotide encoding the same.More preferably, said polypeptide mediating a modified tropism is afusion polypeptide of a viral membrane integral polypeptide or of aviral membrane associated polypeptide with a polypeptide mediatingbinding to a target, e.g. a cell, preferably a specific kind of cell,more preferably a cancer cell. Preferably, said fusion polypeptidecomprises a viral hemagglutinin or a fragment thereof, preferably amembrane integral fragment thereof. Preferably, said fusion polypeptidecomprises a single-chain antibody specifically binding to a targetmolecule, e.g. to Carcinoembryonic antigen (CEA) or CD20. Mostpreferably, said fusion polypeptide is a fusion polypeptide of atruncated viral hemagglutinin with an anti-CD20 single-chain antibody orwith an anti-CEA single-chain antibody. Preferably, the recombinantvirus comprises a polynucleotide comprising the nucleic acid sequence ofany one of SEQ ID Nos: 4 to 7, 14, and 15. SEQ ID NO: 4 is an artificialMV genome encoding an IL-12 fusion polypeptide comprising the mouse p40subunit of IL-12 and the mouse p35 subunit of IL-12 as specifiedelsewhere herein. SEQ ID NO: 5 is an artificial MV genome encoding anIL-12 fusion polypeptide comprising the human p40 subunit of IL-12 andthe human p35 subunit of IL-12 as specified elsewhere herein. SEQ ID NO:6 is an artificial MV genome encoding an IL-12 fusion polypeptidecomprising the mouse p40 subunit of IL-12 and the mouse p35 subunit ofIL-12 as specified elsewhere herein, and a fusion polypeptide comprisinga viral hemagglutinin and an anti-human-CEA single-chain antibody. SEQID NO: 7 is an artificial MV genome encoding an IL-12 fusion polypeptidecomprising the mouse p40 subunit of IL-12 and the mouse p35 subunit ofIL-12 as specified elsewhere herein, and a fusion polypeptide comprisinga viral hemagglutinin and an anti-human-CD20 single-chain antibody. SEQID NO: 14 is an artificial MV genome derived from strain Edmonston Bencoding an IL-12 fusion polypeptide comprising the mouse p40 subunit ofIL-12 and the mouse p35 subunit of IL-12 as specified elsewhere herein.SEQ ID NO: 15 is an artificial MV genome encoding an IL-12 fusionpolypeptide comprising the human p40 subunit of IL-12 and the human p35subunit of IL-12 as specified elsewhere herein.

As used herein, the term “IL-12” relates to an interleukin 12 which is,in principle, known to the skilled person. Preferably, IL-12 is theheterodimeric IL-12 having the activity of stimulating the immuneresponse of a subject. Preferably, the IL-12 is an IL-12 of a vertebratespecies, more preferably of a mammal, even more preferably of a rat, amouse, or a human, most preferably of a human. Preferably, the IL-12 hasthe subunits of rat IL-12, i.e. p35 comprising the amino acid sequenceof Genbank Acc. No: NP_445842.1 GI:16758120, and p40 comprising theamino acid sequence of Genbank Acc. No: NP_072133.1 GI:12018288.Preferably, the subunits of the rat IL-12 are encoded by apolynucleotide comprising the nucleic acid sequence of Genbank Acc. No:NM_053390.1 GI:16758119 (rat mRNA expressed from the rat IL-12A gene)and/or of Genbank Acc. No: NM_022611.1 GI:12018287 (rat mRNA expressedfrom the rat IL-12B gene). More preferably, the IL-12 has the subunitsof mouse IL-12, i.e. p35 comprising the amino acid sequence of GenbankAcc. No: NP_001152896.1 GI:226874945, and p40 comprising the amino acidsequence of Genbank Acc. No: NP_001290173.1 GI:735997434. Preferably,the subunits of the mouse IL-12 are encoded by a polynucleotidecomprising the nucleic acid sequence of Genbank Acc. No: NM_001159424.2GI:746816821 (mouse mRNA expressed from the mouse IL-12A gene) and/or ofGenbank Acc. No: NM_001303244.1 GI:735997433 (mouse mRNA expressed fromthe mouse IL-12B gene). Most preferably, the IL-12 has the subunits ofhuman IL-12, i.e. p35 comprising the amino acid sequence of Genbank Acc.No: NP_000873.2 GI:24430219, and p40 comprising the amino acid sequenceof Genbank Acc. No: NP_002178.2 GI:24497438. Preferably, the subunits ofthe human IL-12 are encoded by a polynucleotide comprising the nucleicacid sequence of Genbank Acc. No: NM_000882.3 GI:325974478 (human mRNAexpressed from the human IL-12A gene) and/or of Genbank Acc. No:NM_002187.2 GI:24497437 (human mRNA expressed from the human IL-12Bgene). In its natural form, IL-12 is a secreted interleukin, i.e. it isprocessed and transported from the interior of the producing cell to theexterior of the producing cell by said producing cell. Accordingly,IL-12 preferably is a secreted IL-12.

More preferably, the IL-12 according to the present invention is anIL-12 fusion polypeptide comprising a p40 subunit of an IL-12 and a p35subunit of an IL-12, preferably comprising subunits as specified hereinabove. More preferably, the p40 subunit and the p35 subunit of saidIL-12 fusion polypeptide are from the same species; i.e. preferably, thep40 subunit and the p35 subunit of said IL-12 fusion polypeptide are arat p40 subunit and a rat p35 subunit, more preferably are a mouse p40subunit and a mouse p35 subunit, most preferably are a human p40 subunitand a human p35 subunit. Preferably, said p40 subunit and said p35subunit are comprised in the order N-terminus- p40 subunit- p35subunit—C-terminus in said fusion polypeptide. Preferably, said p40subunit and said p35 subunit are separated by a linker, i.e., the fusionpolypeptide comprises the structure p40-linker-35.

The term “linker” is known to the skilled person and, preferably,relates to a short sequence of amino acids separating two domains of apolypeptide or two components of a fusion polypeptide. The skilledperson knows how to select appropriate linker sequences in order toconstruct functional fusion polypeptides, e.g. from Xue et al. (2004),NAR 32 (Web server issue):W562. Preferably, said linker comprises offrom 1 to 50, more preferably of from 2 to 25, most preferably of from10 to 20 amino acids. Preferably, the amino acids of the linker aresmall amino acids and/or amino acids promoting turns in proteinstructure; accordingly, the amino acids comprised in the linker,preferably, are glycine, alanine, serine, and/or proline. Preferably,the linker has a repetitive structure; thus, preferably, the linkercomprises of from 1 to 10, more preferably of from 2 to 5, mostpreferably 3 repetitions of an amino acid sequence comprising 3 or 4,preferably 5 amino acids. Preferably, the repetitive sequence of thelinker comprises the sequence (glycine_(x)-serine), with x=3 to 6,preferably 4 to 6, more preferably 4 or 6. More preferably, therepetitive sequence of the linker comprises the sequence(glycine₄-serine), i.e. gly-gly-gly-gly-ser (SEQ ID NO:1), preferablyrepeated as specified above. Thus, preferably the linker comprises orconsists of the amino acid sequence -(glycine₄-serine)_(n)-, with n=1 to10, preferably n=2 to 5, more preferably n=3. Most preferably, thelinker has the amino acid sequence of SEQ ID NO:8. Also more preferably,the repetitive sequence of the linker comprises the sequence(glycine₆-serine), i.e. gly-gly-gly-gly-gly-gly-ser (SEQ ID NO 9).

As used herein, the term “fusion polypeptide” relates to a polypeptidewherein all components, e.g. p35 subunit, linker, and p40 subunit, arecovalently linked and, preferably, are produced as a contiguouspolypeptide chain. Thus, preferably, the fusion polypeptide of thepresent invention, preferably, is expressed from a single gene. Thus,the IL-12 of the present invention preferably is fused mouse IL-12(FmIL-12), preferably comprising the amino acid sequence of SEQ IDNO:10, preferably encoded by a polynucleotide comprising the nucleicacid sequence of SEQ ID NO:11. More preferably, the IL-12 of the presentinvention preferably is fused human IL-12 (FhIL-12), preferablycomprising the amino acid sequence of SEQ ID NO:12, preferably encodedby a polynucleotide comprising the nucleic acid sequence of SEQ IDNO:13.

The terms “polypeptide” and “fusion polypeptide”, as used herein,preferably encompass variants of said polypeptides and fusionpolypeptides as specified elsewhere herein.

Preferably, the recombinant virus of the family Paramyxoviridae of thepresent invention further comprises at least one expressiblepolynucleotide encoding a further activator of the immune response,preferably an immunoglobulin or part thereof, preferably a secretedimmunoglobulin.

As used herein, the term “further activator of the immune response”relates to a compound which, when contacted with a mixture of immunecells and immune-response inducing cells, e.g. cancer cells, causes atleast one type of immune cell to be more active as compared to an immunecell of the same type comprised in the same mixture but lacking saidcompound. As used herein, the term IL-12 as specified elsewhere hereinrelates to an activator of the immune response, but not to a furtheractivator of the immune response. Preferably, the immune cell activatedis a cell mediating a response increasing a subject's resistance to anantigen, i.e. preferably, said immune cell is not a tolerance-mediatingimmune cell. Preferably, the immune cell activated by the furtheractivator of the immune response is a T-cell, more preferably a helperT-cell ora cytotoxic T-cell. Most preferably, the immune cell activatedby the further activator of the immune response is a cytotoxic T-cellexpressing PD-1. Measures of immune cell activity are known to theskilled person and include, preferably, expression of activationmarkers, production of antibodies, excretion of cytokines, and releaseof cytotoxins, e.g. perforin, granzymes, and/or granolysin.

Preferably, the further activator of the immune response is anantagonist of a signaling pathway causing at least one type of immunecell to become inhibited. Accordingly, preferably, the further activatorof the immune response is a ligand for an immune checkpoint blockadeprotein. More preferably, the further activator of the immune responseis a ligand for an immune checkpoint blockade protein. Still morepreferably, the activator of the immune response is an inhibitor of PD-1receptor signaling. It is understood by the skilled person thatsignaling through a receptor signaling pathway can be inhibited byeither preventing the receptor from being activated, or by preventingthe signal generated by the activated receptor from being furthertransmitted. Accordingly, preferably, the further activator of theimmune response is a PD-L1 antagonist, the term “antagonist” relating toa compound binding to the molecule the effect of which is antagonizedand through said binding preventing said molecule from interacting withits native binding partner in a productive, i.e. signaling-inducing,way. Preferred assays for said activity are described e.g. in WO2015/128313 A1.

Preferably, the further activator of the immune response is anantagonist as described above selected from the list of molecule typesconsisting of a peptide aptamer, an anticalin, a Designed Ankyrin RepeatProtein (DARPin), an inhibitory peptide, and, preferably, animmunoglobulin, more preferably, an antibody.

In the context of this invention, a “peptide aptamer” is a peptidespecifically binding its interaction partner and having the activity ofactivating the immune response as specified herein above, preferably,the activity of being an antagonist of PD-L1 as specified herein above.Peptide aptamers, preferably, are peptides comprising 8-80 amino acids,more preferably 10-50 amino acids, and most preferably 15-30 aminoacids. They can e.g. be isolated from randomized peptide expressionlibraries in a suitable host system like baker's yeast (see, forexample, Klevenz et al., Cell Mol Life Sci. 2002, 59: 1993-1998). Apeptide aptamer, preferably, is a free peptide; it is, however, alsocontemplated by the present invention that a peptide aptamer is fused toa polypeptide serving as “scaffold”, meaning that the covalent linkingto said polypeptide serves to fix the three-dimensional structure ofsaid peptide aptamer to one specific conformation. More preferably, thepeptide aptamer is fused to a transport signal, in particular a peptideexport signal.

As used herein, the term “anticalin” relates to an artificialpolypeptide derived from a lipocalin specifically binding itsinteraction partner. Similarly, a “Designed Ankyrin Repeat Protein” or“DARPin”, as used herein, is an artificial polypeptide comprisingseveral 14cab14i14 repeat motifs and specifically binding itsinteraction partner. The anticalins and the DARPins of the presentinvention have the activity of activating the immune response asspecified herein above, preferably, the activity of being an antagonistof PD-L1 as specified herein above.

As used herein, the term “inhibitory peptide” relates to any chemicalmolecule comprising at least one peptide having the activity ofactivating the immune response as specified herein above, preferably,the activity of being an antagonist PD-L1 as specified herein above.Preferably, the inhibitory peptide comprises a peptide having an aminoacid sequence corresponding to an amino acid sequence of at least five,at least six, at least seven, at least eight, at least nine, at leastten, at least eleven, at least twelve, at least 13, at least 14, or atleast 15 consecutive amino acids comprised in a PD-L1 polypeptide.Preferably, the inhibitory peptide comprises a peptide having an aminoacid sequence corresponding to an amino acid sequence of 5 to 200, morepreferably 6 to 100, even more preferably 7 to 50, or, most preferably,8 to 30 consecutive amino acids comprised in a PD-L1 polypeptide.Moreover, also encompassed are variants of the aforementioned inhibitorypeptides. Such variants have at least the same essential biologicalactivity as the specific inhibitory peptides.

As used herein, the term “immunoglobulin” relates to a polypeptide beinga soluble immunoglobulin, preferably an antibody from any of the classesIgA, IgD, IgE, IgG, or IgM, preferably having the activity of binding,more preferably specifically binding, a molecule of interest.Immunoglobulins against antigens of interest can be prepared by wellknown methods using, e.g., a purified molecule of interest or a suitablefragment derived therefrom as an antigen. A fragment which is suitableas an antigen may be identified by antigenicity determining algorithmswell known in the art. Such fragments may be obtained either from one ofthe molecules of interest by proteolytic digestion, may be a syntheticpeptide, or may be obtained by recombinant expression. Preferably, apeptide of a molecule of interest used as an antigen is located at theexterior of a cell expressing the molecule of interest; i.e. preferably,the epitope the binding domain interacts with, preferably, is anextracellular domain. Preferably, the immunoglobulin of the presentinvention is a monoclonal antibody, a human or humanized antibody orprimatized, chimerized antibody or a fragment thereof, so long as theyexhibit the desired binding activity as specified elsewhere herein. Alsocomprised as antibodies of the present invention are a bispecificantibody, a synthetic antibody, or a chemically modified derivative ofany of these. Preferably, the antibody of the present invention shallspecifically bind (i.e. does only to a negligible extent or, preferably,not cross react with other polypeptides or peptides) to a molecule ofinterest as specified above. Specific binding can be tested by variouswell known techniques. Antibodies or fragments thereof can be obtainedby using methods which are described, e.g., in Harlow and Lane“Antibodies, A Laboratory Manual”, CSH Press, Cold Spring Harbor, 1988.Monoclonal antibodies can be prepared by the techniques originallydescribed in Köhler and Milstein, Nature. 1975. 256: 495; and Galfré,Meth. Enzymol. 1981, 73: 3, which comprise the fusion of mouse myelomacells to spleen cells derived from immunized mammals. As will beunderstood by the skilled person, a molecule of interest, bound by animmunoglobulin of the present invention, may also be an Fc receptor or acomplement protein binding an Fc part of an antibody; accordingly, theimmunoglobulin preferably is an Fc domain of an antibody, morepreferably a soluble Fc domain of an antibody, most preferably asecreted soluble Fc domain of an antibody. Preferably, said antibody theFc domain is derived from is an IgG, more preferably an IgG1, mostpreferably a human IgG1. Preferably, the secreted soluble Fc domaincomprises the amino acid sequence of SEQ ID NO: 16 or a variant thereof,preferably encoded by the nucleic acid sequence of SEQ ID NO: 17. Morepreferably, the immunoglobulin is an antagonistic anti-PD-L1 antibody,still more preferably comprising the amino acid sequence of SEQ ID NO:2or a variant thereof, preferably encoded by a polynucleotide comprisingthe nucleic acid sequence of SEQ ID NO:3 or a variant thereof. Morepreferably, the immunoglobulin is an antagonistic anti-PD-L1 antibody,more preferably comprising the amino acid sequence of SEQ ID NO:2,preferably encoded by a polynucleotide comprising the nucleic acidsequence of SEQ ID NO:3.

“Immunoglobulin fragments” comprise a portion of an intactimmunoglobulin, preferably of an antibody, in an embodiment, comprisethe antigen-binding region thereof. Examples of antibody fragments andfusion proteins of variable regions include Fab, Fab′, F(ab′)2, and Fvfragments; diabodies; linear antibodies; single-chain antibodymolecules; single-domain-antibodies (VHH), also known as nanobodies, andmultispecific antibodies formed from antibody fragments. Papaindigestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab')2 fragment thathas two antigen-combining sites and is still capable of cross-linkingantigen. “Fv” is the minimum antibody fragment which contains a completeantigen-binding site. Preferably, a two-chain Fv species consists of adimer of one heavy- and one light-chain variable domain in tight,non-covalent association. In a single-chain Fv (scFv) species, oneheavy- and one light-chain variable domain can be covalently linked by aflexible peptide linker such that the light and heavy chains canassociate in a “dimeric” structure analogous to that in a two-chain Fvspecies. It is in this configuration that the three hypervariableregions (HVRs, also referred to as complementarity determining regions(CDRs)) of each variable domain interact to define an antigen-bindingsite. Collectively, the six HVRs of one scFv confer antigen-bindingspecificity to the antibody. However, even a single variable domain (orhalf of an Fv comprising only three HVRs specific for an antigen) hasthe ability to recognize and bind antigen, although at a lower affinitythan the entire binding site. The term “diabodies” refers to antibodyfragments with two antigen-binding sites, which fragments comprise aheavy-chain variable domain (VH) connected to a light-chain variabledomain (VL) in the same polypeptide chain (VH-VL). By using a linkerthat is too short to allow pairing between the two domains on the samechain, the domains are forced to pair with the complementary domains ofanother chain and create two antigen-binding sites. Diabodies may bebivalent or bispecific. Diabodies are described more fully in, forexample, EP 0 404 097; WO 1993/01161; Hudson et al., Nat. Med. 9 (2003)129-134; and Hollinger et al., PNAS USA 90 (1993) 6444-6448. Triabodiesand tetrabodies are also described in Hudson et al., Nat. Med. 9 (2003)129-134.

The term “secreted”, as used herein, relates to a compound beingtransferred from the interior of a host cell to the exterior of saidhost cell by a mechanism intrinsic to said host cell. Preferably,secretion of a polypeptide or fusion polypeptide is mediated by a,preferably eukaryotic, signal peptide mediating import of said peptideor polypeptide into the lumen of the endoplasmic reticulum and, morepreferably, by the absence of retention signals. Signal peptides causingsecretion of peptides or polypeptides are known in the art. Preferably,the signal peptide is an IL-12 signal peptide. Also preferably, thesignal peptide is or comprises an Ig leader sequence. More preferably,the signal peptide is or comprises a human Ig leader sequence. Stillmore preferably, the signal peptide is or comprises a matching leadersequence, i.e. a leader sequence selected from the same Ig kappasubgroup as the variable light chain of the antibody, preferably, of thesingle-chain antibody.

As used herein, the terms “polypeptide variant” relates to any chemicalmolecule comprising at least one polypeptide or fusion polypeptide asspecified elsewhere herein, having the indicated activity, but differingin primary structure from said polypeptide or fusion polypeptideindicated above. Thus, the polypeptide variant, preferably, is a muteinhaving the indicated activity. Preferably, the polypeptide variantcomprises a peptide having an amino acid sequence corresponding to anamino acid sequence of 5 to 200, more preferably 6 to 100, even morepreferably 7 to 50, or, most preferably, 8 to 30 consecutive amino acidscomprised in a polypeptide as specified above. Moreover, alsoencompassed are further polypeptide variants of the aforementionedpolypeptides. Such polypeptide variants have at least essentially thesame biological activity as the specific polypeptides. Moreover, it isto be understood that a polypeptide variant as referred to in accordancewith the present invention shall have an amino acid sequence whichdiffers due to at least one amino acid substitution, deletion and/oraddition, wherein the amino acid sequence of the variant is still,preferably, at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%,or 99% identical with the amino acid sequence of the specificpolypeptide. The degree of identity between two amino acid sequences canbe determined by algorithms well known in the art. Preferably, thedegree of identity is to be determined by comparing two optimallyaligned sequences over a comparison window, where the fragment of aminoacid sequence in the comparison window may comprise additions ordeletions (e.g., gaps or overhangs) as compared to the sequence it iscompared to for optimal alignment. The percentage is calculated bydetermining, preferably over the whole length of the polypeptide, thenumber of positions at which the identical amino acid residue occurs inboth sequences to yield the number of matched positions, dividing thenumber of matched positions by the total number of positions in thewindow of comparison and multiplying the result by 100 to yield thepercentage of sequence identity. Optimal alignment of sequences forcomparison may be conducted by the local homology algorithm of Smith andWaterman (1981), by the homology alignment algorithm of Needleman andWunsch (1970), by the search for similarity method of Pearson and Lipman(1988), by computerized implementations of these algorithms (GAP,BESTFIT, BLAST, PASTA, and TFASTA in the Wisconsin Genetics SoftwarePackage, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.),or by visual inspection. Given that two sequences have been identifiedfor comparison, GAP and BESTFIT are preferably employed to determinetheir optimal alignment and, thus, the degree of identity. Preferably,the default values of 5.00 for gap weight and 0.30 for gap weight lengthare used. Polypeptide variants referred to herein may be allelicvariants or any other species specific homologs, paralogs, or orthologs.Moreover, the polypeptide variants referred to herein include fragmentsof the specific polypeptides or the aforementioned types of polypeptidevariants as long as these fragments and/or variants have the biologicalactivity as referred to above. Such fragments may be or be derived from,e.g., degradation products or splice variants of the polypeptides.Further included are variants which differ due to posttranslationalmodifications such as phosphorylation, glycosylation, ubiquitinylation,sumoylation, or myristylation, by including non-natural amino acids,and/or by being peptidomimetics.

The term “expressible polynucleotide”, as used herein, relates to apolynucleotide operatively linked to at least one expression controlsequence causing transcription of the nucleic acid sequence comprised insaid polynucleotide to occur, preferably in eukaryotic cells or isolatedfractions thereof, preferably into a translatable mRNA or into a viralgenome. Regulatory elements ensuring expression in eukaryotic cells,preferably mammalian cells, are well known in the art. They, preferably,comprise regulatory sequences ensuring initiation of transcription and,optionally, poly-A signals ensuring termination of transcription andstabilization of the transcript. Additional regulatory elements mayinclude transcriptional as well as translational enhancers. Preferably,the aforesaid at least one expression control sequence is an expressioncontrol sequence of a (−)strand RNA virus, more preferably of aParamyxovirus as described herein above, most preferably of an MV. Thus,preferably, at least one expression control sequence comprises a(−)strand RNA viral regulatory sequence ensuring initiation oftranscription (consensus “gene start signal”, preferably consensus MV“gene start signal”) and termination signals (consensus “gene stopsignal”, preferably, consensus MV “gene stop signal”) ensuringtermination of transcription and stabilization of the transcript. It isknown in the art that production of viral particles in permissive hostcells can be initiated by transfecting into said permissive host cellsone or more expressible DNA constructs encoding (i) a recombinant viralanti-genome, (ii) the viral L gene, (iii) the viral P gene, and (iv) theviral N gene. It is also understood by the skilled person that, once aviral genome and the aforesaid viral genes were expressed in said hostcell, replication and assembly of viral particles occurs in thecytoplasm of the host cell and is, therefore, solely dependent on viralregulatory signals. The term polynucleotide, as used herein, preferablyencompasses polynucleotide variants as specified elsewhere herein.Preferably, the expressible polynucleotide encoding an IL-12 iscomprised in the genome of the recombinant virus of the familyParamyxoviridae in a region corresponding to the region intervening theP and the M gene of measles virus.

The term “polynucleotide encoding a recombinant virus”, as used herein,relates to a polynucleotide comprising a nucleic acid sequence ornucleic acid sequences required for generating a virus particle or avirus-like particle in a host cell. It is understood by the skilledperson that a virus is constituted by a polynucleotide genome and atleast one kind of capsid polypeptide. Accordingly, the polynucleotideencoding a recombinant virus of the present invention, preferably,comprises a recombinant virus genome. As will be understood by theskilled person, in case the polynucleotide encoding a recombinant virusis comprised in a virus according to the present invention, i.e. a virusof the family Paramyxoviridae, the polynucleotide is (−)strand RNA. Itis also understood by the skilled person that in case the polynucleotideis DNA comprised in a host cell, at least an RNA-dependent RNApolymerase activity will additionally be required to produce viralparticles from said DNA polynucleotide. Preferably, the polynucleotideencoding a recombinant virus comprises or consists of the nucleic acidsequence as specified elsewhere herein. As annotated herein, thesequence of the DNA copy of negative-strand (−)RNA viruses is annotatedin the usual 5′→3′-orientation; this corresponds to the viral sequencein antigenomic (+)RNA orientation with respect to the natural3′→5′-orientation of negative-strand (−)RNA viruses.

The term “polynucleotide variant”, as used herein, relates to a variantof a polynucleotide related to herein comprising a nucleic acid sequencecharacterized in that the sequence can be derived from theaforementioned specific nucleic acid sequence by at least one nucleotidesubstitution, addition and/or deletion, wherein the polynucleotidevariant shall have the activity as specified for the specificpolynucleotide. Preferably, said polynucleotide variant is an ortholog,a paralog or another homolog of the specific polynucleotide. Alsopreferably, said polynucleotide variant is a naturally occurring alleleof the specific polynucleotide. Polynucleotide variants also encompasspolynucleotides comprising a nucleic acid sequence which is capable ofhybridizing to the aforementioned specific polynucleotides, preferably,under stringent hybridization conditions. These stringent conditions areknown to the skilled worker and can be found in Current Protocols inMolecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Apreferred example for stringent hybridization conditions arehybridization conditions in 6× sodium chloride/sodium citrate (=SSC) atapproximately 45° C., followed by one or more wash steps in 0.2× SSC,0.1% SDS at 50 to 65° C. The skilled worker knows that thesehybridization conditions differ depending on the type of nucleic acidand, for example when organic solvents are present, with regard to thetemperature and concentration of the buffer. For example, under“standard hybridization conditions” the temperature differs depending onthe type of nucleic acid between 42° C. and 58° C. in aqueous bufferwith a concentration of 0.1× to 5× SSC (pH 7.2). If organic solvent ispresent in the abovementioned buffer, for example 50% formamide, thetemperature under standard conditions is approximately 42° C. Thehybridization conditions for DNA:DNA hybrids are preferably for example0.1x SSC and 20° C. to 45° C., preferably between 30° C. and 45° C. Thehybridization conditions for DNA:RNA hybrids are preferably, forexample, 0.1× SSC and 30° C. to 55° C., preferably between 45° C. and55° C. The abovementioned hybridization temperatures are determined forexample for a nucleic acid with approximately 100 bp (=base pairs) inlength and a G+C content of 50% in the absence of formamide. The skilledworker knows how to determine the hybridization conditions required byreferring to textbooks such as the textbook mentioned above, or thefollowing textbooks: Sambrook et al., “Molecular Cloning”, Cold SpringHarbor Laboratory, 1989; Hames and Higgins (Ed.) 1985, “Nucleic AcidsHybridization: A Practical Approach”, IRL Press at Oxford UniversityPress, Oxford; Brown (Ed.) 1991, “Essential Molecular Biology: APractical Approach”, IRL Press at Oxford University Press, Oxford.Alternatively, polynucleotide variants are obtainable by PCR-basedtechniques such as mixed oligonucleotide primer-based amplification ofDNA, i.e. using degenerated primers against conserved domains of apolypeptide of the present invention. Conserved domains of a polypeptidemay be identified by a sequence comparison of the nucleic acid sequenceof the polynucleotide or the amino acid sequence of the polypeptide ofthe present invention with sequences of other organisms. As a template,DNA or cDNA from bacteria, fungi, or plants preferably, from animals maybe used. Further, variants include polynucleotides comprising nucleicacid sequences which are at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 95%, at least 98% or at least 99%identical to the specifically indicated nucleic acid sequences.Moreover, also encompassed are polynucleotides which comprise nucleicacid sequences encoding amino acid sequences which are at least 70%, atleast 75%, at least 80%, at least 85%, at least 90%, at least 95%, atleast 98% or at least 99% identical to the amino acid sequencesspecifically indicated. The percent identity values are, preferably,calculated over the entire amino acid or nucleic acid sequence region. Aseries of programs based on a variety of algorithms is available to theskilled worker for comparing different sequences. In this context, thealgorithms of Needleman and Wunsch or Smith and Waterman giveparticularly reliable results. To carry out the sequence alignments, theprogram PileUp (J. Mol. Evolution., 25, 351-360, 1987, Higgins et al.,CABIOS, 5 1989: 151-153) or the programs Gap and BestFit (Needleman andWunsch (J. Mol. Biol. 48; 443-453 (1970)) and Smith and Waterman (Adv.Appl. Math. 2; 482-489 (1981))), which are part of the GCG softwarepacket (Genetics Computer Group, 575 Science Drive, Madison, Wis., USA53711 (1991)), are to be used. The sequence identity values recitedabove in percent (%) are to be determined, preferably, using the programGAP over the entire sequence region with the following settings: GapWeight: 50, Length Weight: 3, Average Match: 10.000 and AverageMismatch: 0.000, which, unless otherwise specified, shall always be usedas standard settings for sequence alignments.

A polynucleotide comprising a fragment of any of the specificallyindicated nucleic acid sequences is also encompassed as a variantpolynucleotide of the present invention. The fragment shall still encodea polypeptide or fusion polypeptide which still has the activity asspecified. Accordingly, the polypeptide encoded may comprise or consistof the domains of the polypeptide of the present invention conferringthe said biological activity. A fragment as meant herein, preferably,comprises at least 50, at least 100, at least 250 or at least 500consecutive nucleotides of any one of the specific nucleic acidsequences or encodes an amino acid sequence comprising at least 20, atleast 30, at least 50, at least 80, at least 100 or at least 150consecutive amino acids of any one of the specific amino acid sequences.

The polynucleotides of the present invention either consist of,essentially consist of, or comprise the aforementioned nucleic acidsequences. Thus, they may contain further nucleic acid sequences aswell. Specifically, the polynucleotides of the present invention mayencode fusion proteins wherein one partner of the fusion protein is apolypeptide being encoded by a nucleic acid sequence recited above. Suchfusion proteins may comprise as additional part polypeptides formonitoring expression (e.g., green, yellow, blue or red fluorescentproteins, alkaline phosphatase and the like) or so called “tags” whichmay serve as a detectable marker or as an auxiliary measure forpurification purposes. Tags for the different purposes are well known inthe art and are described elsewhere herein.

The polynucleotide of the present invention shall be provided,preferably, either as an isolated polynucleotide (i.e. isolated from itsnatural context) or in genetically modified form. The polynucleotide,preferably, is DNA, including cDNA, or RNA. The term encompasses singleas well as double stranded polynucleotides. Moreover, preferably,comprised are also chemically modified polynucleotides includingnaturally occurring modified polynucleotides such as glycosylated ormethylated polynucleotides or artificial modified one such asbiotinylated polynucleotides.

As used herein, the term “host cell” relates to a vertebrate cell.Preferably, the cell is a mammalian cell, more preferably, a mouse, rat,cat, dog, hamster, guinea pig, sheep, goat, pig, cattle, or horse cell.Still more preferably, the host cell is a primate cell. Most preferably,the host cell is a human cell. Preferably, the host cell is a tumorcell, more preferably a cancer cell.

Advantageously, it was found in the work underlying the presentinvention that oncolytic measles virus can be engineered to expressIL-12, in particular an IL-12 fusion polypeptide, while infecting cancercells and that IL-12 expression strongly enhances the immune responseinduced by the measles virus against said cancer cells. Moreover, it wasfound that by further expressing immunoglobulins, in particular ananti-PD-L1 antibody, measles virus can further augment the immunologicalresponse to cancer cells, thus further contributing to theirelimination.

The definitions made above apply mutatis mutandis to the following.Additional definitions and explanations made further below also applyfor all embodiments described in this specification mutatis mutandis.

The present invention further relates to a polynucleotide encoding therecombinant virus of the family Paramyxoviridae according to the presentinvention.

The present invention further relates to a host cell comprising therecombinant virus of the family Paramyxoviridae of the present inventionand/or the polynucleotide encoding the recombinant virus of the familyParamyxoviridae of the present invention.

As used herein, the term “host cell” relates to a host cell as specifiedherein above. Moreover, the host cell comprising the polynucleotideencoding the recombinant virus of the family Paramyxoviridae of thepresent invention may also be a bacterial, yeast, or insect cell,preferably a bacterial cell of the genus Escherichia, more preferably anEscherichia coli cell.

The present invention also relates to a medicament comprising (a) (i) arecombinant virus of the family Paramyxoviridae comprising anexpressible polynucleotide encoding an IL-12 and not comprising anexpressible polynucleotide encoding a CTLA-4 antagonist, a PD-1antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;(ii) a recombinant virus of the family Paramyxoviridae comprising anexpressible polynucleotide encoding an IL-12 fusion polypeptide of thepresent invention; (iii) a polynucleotide encoding the recombinant virusof the family Paramyxoviridae of (i) and/or (ii), (iv) a host cellcomprising the recombinant virus of the family Paramyxoviridae and/orthe polynucleotide encoding the recombinant virus of the familyParamyxoviridae according to; or (v) any combination of (i) to (iv); and(b) at least one pharmacologically acceptable excipient.

The terms “medicament” and “pharmaceutical composition”, as used herein,relate to the compounds of the present invention and optionally one ormore pharmaceutically acceptable carrier, i.e. excipient. The compoundsof the present invention can be formulated as pharmaceuticallyacceptable salts. Acceptable salts comprise acetate, methyl ester, HCI,sulfate, chloride and the like. The pharmaceutical compositions are,preferably, administered locally, topically or systemically. Suitableroutes of administration conventionally used for drug administration areoral, intravenous, or parenteral administration as well as inhalation. Apreferred route of administration is intra-tumoral administration.However, depending on the nature and mode of action of a compound, thepharmaceutical compositions may be administered by other routes as well.For example, polynucleotide compounds may be administered in a genetherapy approach by using viral vectors or viruses or liposomes.

Moreover, the compounds can be administered in combination with otherdrugs either in a common pharmaceutical composition or as separatedpharmaceutical compositions wherein said separated pharmaceuticalcompositions may be provided in form of a kit of parts. The compoundsare, preferably, administered in conventional dosage forms prepared bycombining the drugs with standard pharmaceutical carriers according toconventional procedures. These procedures may involve mixing,granulating and compressing or dissolving the ingredients as appropriateto the desired preparation. It will be appreciated that the form andcharacter of the pharmaceutically acceptable carrier or diluent isdictated by the amount of active ingredient with which it is to becombined, the route of administration and other well-known variables.

The excipient(s) must be acceptable in the sense of being compatiblewith the other ingredients of the formulation and being not deleteriousto the recipient thereof. The excipient employed may be, for example, asolid, a gel or a liquid carrier. Exemplary of solid carriers arelactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia,magnesium stearate, stearic acid and the like. Exemplary of liquidcarriers are phosphate buffered saline solution, syrup, oil such aspeanut oil and olive oil, water, emulsions, various types of wettingagents, sterile solutions and the like. Similarly, the carrier ordiluent may include time delay material well known to the art, such asglyceryl mono-stearate or glyceryl distearate alone or with a wax. Saidsuitable carriers comprise those mentioned above and others well knownin the art, see, e.g., Remington's Pharmaceutical Sciences, MackPublishing Company, Easton, Pa. The diluent(s) is/are selected so as notto affect the biological activity of the combination. Examples of suchdiluents are distilled water, physiological saline, Ringer's solutions,dextrose solution, and Hank's solution. In addition, the pharmaceuticalcomposition or formulation may also include other carriers, adjuvants,or nontoxic, nontherapeutic, non-immunogenic stabilizers and the like.

A therapeutically effective dose refers to an amount of the compounds tobe used in a pharmaceutical composition of the present invention whichprevents, ameliorates or treats the symptoms accompanying a disease orcondition referred to in this specification. Therapeutic efficacy andtoxicity of such compounds can be determined by standard pharmaceuticalprocedures in cell cultures or experimental animals, e.g., ED50 (thedose therapeutically effective in 50% of the population) and LD50 (thedose lethal to 50% of the population). The dose ratio betweentherapeutic and toxic effects is the therapeutic index, and it can beexpressed as the ratio, LD50/ED50.

The dosage regimen will be determined by the attending physician andother clinical factors; preferably in accordance with any one of theabove described methods. As is well known in the medical arts, dosagesfor any one patient depends upon many factors, including the patient'ssize, body surface area, age, the particular compound to beadministered, sex, time and route of administration, general health, andother drugs being administered concurrently. Progress can be monitoredby periodic assessment. A typical dose can be, for example, in the rangeof 1 to 1000 μg for a polypeptide or polynucleotide, or 10⁴-10⁸ viralparticles for a virus or a virus-like particle; however, doses below orabove this exemplary range are envisioned, especially considering theaforementioned factors. Progress can be monitored by periodicassessment. The pharmaceutical compositions and formulations referred toherein are administered at least once in order to treat or ameliorate orprevent a disease or condition recited in this specification. However,the said pharmaceutical compositions may be administered more than onetime, for example from one to four times daily up to a non-limitednumber of days. Specific pharmaceutical compositions are prepared in amanner well known in the pharmaceutical art and comprise at least oneactive compound referred to herein above in admixture or otherwiseassociated with a pharmaceutically acceptable carrier or diluent. Formaking those specific pharmaceutical compositions, the activecompound(s) will usually be mixed with a carrier or the diluent, orenclosed or encapsulated in a capsule, sachet, cachet, paper or othersuitable containers or vehicles. The resulting formulations are to beadapted to the mode of administration, i.e. in the forms of tablets,capsules, suppositories, solutions, suspensions or the like. Dosagerecommendations shall be indicated in the prescribers or usersinstructions in order to anticipate dose adjustments depending on theconsidered recipient.

Accordingly, the present invention also relates to a method for treatingcancer in a subject afflicted with cancer, comprising

-   a) contacting said subject with    -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae        comprising an expressible polynucleotide encoding an IL-12        fusion polypeptide of the present invention;    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide        encoding the recombinant virus of the family Paramyxoviridae        according to (iii); or    -   (v) any combination of (i) to (iv), and thereby,-   b) treating cancer in a subject afflicted with cancer.

The methods of treatment of the present invention, preferably, maycomprise steps in addition to those explicitly mentioned above. Forexample, further steps may relate, e.g., to localizing a tumor and/ordiagnosing cancer for step a), or administration of additionalmedication for step b). Moreover, one or more of said steps may beperformed by automated equipment. The method of the present invention,preferably, is an in vivo method of treatment.

The term “treatment” refers to an amelioration of the diseases ordisorders referred to herein or the symptoms accompanied therewith to asignificant extent. Said treating as used herein also includes an entirerestoration of the health with respect to the diseases or disordersreferred to herein. It is to be understood that treating as used inaccordance with the present invention may not be effective in allsubjects to be treated. However, the term shall require that,preferably, a statistically significant portion of subjects sufferingfrom a disease or disorder referred to herein can be successfullytreated. Whether a portion is statistically significant can bedetermined without further ado by the person skilled in the art usingvarious well known statistic evaluation tools, e.g., determination ofconfidence intervals, p-value determination, Student's t-test,Mann-Whitney test etc. Preferred confidence intervals are at least 90%,at least 95%, at least 97%, at least 98% or at least 99%. The p-valuesare, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001. Preferably, thetreatment shall be effective for at least 10%, at least 20% at least50%at least 60%, at least 70%, at least 80%, or at least 90% of thesubjects of a given cohort or population. Preferably, treating cancer isreducing tumor burden in a subject. As will be understood by the skilledperson, effectiveness of treatment of e.g. cancer is dependent on avariety of factors including, e.g. cancer stage and cancer type.

As used herein, the term “subject” relates to a vertebrate. Preferably,the subject is a mammal, more preferably, a mouse, rat, cat, dog,hamster, guinea pig, sheep, goat, pig, cattle, or horse. Still morepreferably, the subject is a primate. Most preferably, the subject is ahuman. Preferably, the subject is afflicted with a disease caused oraggravated by an insufficient response of the immune response of saidsubject, more preferably, the subject is afflicted with cancer.

The term “cancer”, as used herein, relates to a disease of an animal,including man, characterized by uncontrolled growth by a group of bodycells (“cancer cells”). This uncontrolled growth may be accompanied byintrusion into and destruction of surrounding tissue and possibly spreadof cancer cells to other locations in the body. Preferably, alsoincluded by the term cancer is a relapse. Thus, preferably, the canceris a solid cancer, a metastasis, or a relapse thereof.

Preferably, the cancer is selected from the list consisting of acutelymphoblastic leukemia, acute myeloid leukemia, adrenocorticalcarcinoma, aids-related lymphoma, anal cancer, appendix cancer,astrocytoma, atypical teratoid, basal cell carcinoma, bile duct cancer,bladder cancer, brain stem glioma, breast cancer, burkitt lymphoma,carcinoid tumor, cerebellar astrocytoma, cervical cancer, chordoma,chronic lymphocytic leukemia, chronic myelogenous leukemia, coloncancer, colorectal cancer, craniopharyngioma, endometrial cancer,ependymoblastoma, ependymoma, esophageal cancer, extracranial germ celltumor, extragonadal germ cell tumor, extrahepatic bile duct cancer,fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinalstromal tumor, gestational trophoblastic tumor, hairy cell leukemia,head and neck cancer, hepatocellular cancer, 27cab27i27 lymphoma,hypopharyngeal cancer, hypothalamic and visual pathway glioma,intraocular melanoma, 27cab27i sarcoma, laryngeal cancer,medulloblastoma, medulloepithelioma, melanoma, merkel cell carcinoma,mesothelioma, mouth cancer, multiple endocrine neoplasia syndrome,multiple myeloma, mycosis fungoides, nasal cavity and paranasal sinuscancer, nasopharyngeal cancer, neuroblastoma, non-hodgkin lymphoma,non-small cell lung cancer, oral cancer, oropharyngeal cancer,osteosarcoma, ovarian cancer, ovarian epithelial cancer, ovarian germcell tumor, ovarian low malignant potential tumor, pancreatic cancer,papillomatosis, paranasal sinus and nasal cavity cancer, parathyroidcancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitarytumor, pleuropulmonary blastoma, primary central nervous systemlymphoma, prostate cancer, rectal cancer, renal cell cancer,retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sézarysyndrome, small cell lung cancer, small intestine cancer, soft tissuesarcoma, squamous cell carcinoma, squamous neck cancer, testicularcancer, throat cancer, thymic carcinoma, thymoma, thyroid cancer,urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer,waldenström macroglobulinemia, and wilms tumor. More preferably, thecancer is a solid cancer, a metastasis, or a relapse thereof. Mostpreferably, the cancer is a tumor derived from malignant melanoma, headand neck cancer, hepatocellular carcinoma, pancreatic carcinoma,prostate cancer, renal cell carcinoma, gastric carcinoma, colorectalcarcinoma, lymphomas or leukemias.

Preferably, the method of treatment of the present invention comprisescontacting a subject with a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 and not comprising an expressible polynucleotide encoding a CTLA-4antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, ora PD-L1 antagonist. Thus, preferably, the method comprises contacting asubject with a recombinant virus of the family Paramyxoviridaecomprising an expressible polynucleotide encoding an IL-12, wherein saidrecombinant virus of the family Paramyxoviridae is not a virus disclosedin WO 2015/128313 A1. Preferably, said recombinant virus of the familyParamyxoviridae of (i) is a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 polypeptide and not comprising an expressible polynucleotideencoding a ligand for an immune checkpoint blockade protein. Morepreferably, the recombinant virus of the family Paramyxoviridae of (i)is a recombinant virus of the family Paramyxoviridae comprising anexpressible polynucleotide encoding an IL-12 polypeptide as the onlyexpressible polynucleotide encoding an activator of the immune response,i. e. preferably, the recombinant virus of the family Paramyxoviridaecomprising an expressible polynucleotide encoding an IL-12 does notcomprise an expressible polynucleotide encoding a further activator ofthe immune response.

The present invention further relates to an in vitro method foractivating immune cells with antitumor activity in a sample comprisingcancer cells and immune cells, comprising

-   a) contacting said sample comprising cancer cells and immune cells    with    -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae        comprising an expressible polynucleotide encoding an IL-12        fusion polypeptide of the present invention;    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide        encoding the recombinant virus of the family Paramyxoviridae        according to (iii); or    -   (v) any combination of (i) to (iv), and thereby,-   b) activating immune cells with antitumor activity comprised in said    sample.

The method for activating immune cells with antitumor activity maycomprise steps in addition to those explicitly mentioned above. Forexample, further steps may relate, e.g., to providing the recombinantvirus of the family Paramyxoviridae for step a), administering furtheractivating compounds, e.g. cytokines, to the immune cells in step b), orseparating immune cells from cancer cells after step b). Moreover, oneor more of said steps may be performed by automated equipment.

Moreover, the present invention relates to a recombinant virus of thefamily Paramyxoviridae of the present invention for use in treatment ofinappropriate cell proliferation.

The term “inappropriate cell proliferation” relates to any proliferationof cells of a subject which is not appropriate to the physiologicalstate of said subject and/or to the tissue context of said cells.Preferably, inappropriate cell proliferation is caused or aggravated byan inhibition or insufficient activation of the immune system, morepreferably inhibition or insufficient activation of T cells. Alsopreferably, inappropriate cell proliferation is cancer.

The present invention further relates to a kit comprising at least

-   -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae        comprising an expressible polynucleotide encoding an IL-12        fusion polypeptide of the present invention;    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide        encoding the recombinant virus of the family Paramyxoviridae        according to (iii); or    -   (v) any combination of (i) to (iv),    -   housed in a container.

The term “kit”, as used herein, refers to a collection of theaforementioned components. Preferably, said components are combined withadditional components, preferably within an outer container. The outercontainer, also preferably, comprises instructions for carrying out amethod of the present invention. Examples for such the components of thekit as well as methods for their use have been given in thisspecification. The kit, preferably, contains the aforementionedcomponents in a ready-to-use formulation. Preferably, the kit mayadditionally comprise instructions, e.g., a user's manual for applyingthe recombinant virus of the family Paramyxoviridae with respect to theapplications provided by the methods of the present invention. Detailsare to be found elsewhere in this specification. Additionally, suchuser's manual may provide instructions about correctly using thecomponents of the kit. A user's manual may be provided in paper orelectronic form, e.g., stored on CD or CD ROM. The present inventionalso relates to the use of said kit in any of the methods according tothe present invention.

Moreover, the present invention relates to a use of

-   -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae        comprising an expressible polynucleotide encoding an IL-12        fusion polypeptide of the present invention;    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae of (i) and/or (ii) and/or the polynucleotide        encoding the recombinant virus of the family Paramyxoviridae        according to (iii); or    -   (v) any combination of (i) to (iv),    -   for the manufacture of a medicament for treating inappropriate        cell proliferation, preferably for treating cancer.

Summarizing the findings of the present invention, the followingembodiments are preferred:

1. A recombinant virus of the family Paramyxoviridae, comprising anexpressible polynucleotide encoding an IL-12 polypeptide, wherein saidIL-12 polypeptide is an IL-12 fusion polypeptide comprising a p40subunit of an IL-12 and a p35 subunit of an IL-12.

2. The recombinant virus of the family Paramyxoviridae of embodiment 1,wherein said p40 subunit and said p35 subunit of said IL-12 fusionpolypeptide are from the same species.

3. The recombinant virus of the family Paramyxoviridae of embodiment 1or 2, wherein said p40 subunit and said p35 subunit of said IL-12 fusionpolypeptide are a mouse p40 subunit and a mouse p35 subunit or a variantthereof, preferably are a human p40 subunit and a human p35 subunit or avariant thereof.

4. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 3, wherein said p40 subunit and said p35 subunit ofsaid IL-12 fusion polypeptide are a Claim subunit and a mouse p35subunit, preferably are a human p40 subunit and a human p35 subunit.

5. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 4, wherein said IL-12 fusion polypeptide comprises thestructure p40-linker-p35.

6. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 5, wherein said linker is -(glycine₄-serine)_(n)-, withn=1 to 10, preferably n=2 to 5, more preferably n=3.

7. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 5, wherein said linker is -(glycine₆-serine)-.

8. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 7, wherein said expressible polynucleotide encoding anIL-12 is comprised in the genome of the recombinant virus of the familyParamyxoviridae in a region corresponding to the region intervening theP and the M gene of measles virus.

9. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 8, further comprising at least one expressiblepolynucleotide encoding a further activator of the immune response.

10. The recombinant virus of the family Paramyxoviridae of embodiment 9,wherein said further activator of the immune response is animmunoglobulin or fragment thereof.

11. The recombinant virus of the family Paramyxoviridae of embodiments 9or 10, wherein said further activator of the immune response is asecreted immunoglobulin.

12. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 9 to 11, wherein said further activator of the immuneresponse is an Fc domain of an antibody.

13. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 9 to 12, wherein said further activator of the immuneresponse is a secreted soluble Fc domain of a human IgG1 antibody.

14. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 9 to 13, wherein said further activator of the immuneresponse is a secreted soluble activator of the immune response.

15. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 9 to 14, wherein said further activator of the immuneresponse is a single-chain antibody or a nanobody.

16. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 9 to 15, wherein said further activator of the immuneresponse is a secreted soluble anti-PD-L1 antibody.

17. The recombinant virus of the family Paramyxoviridae of embodiment16, wherein said secreted soluble anti-PD-L1 antibody comprises an aminoacid sequence according to SEQ ID NO: 2.

18. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 17, wherein said recombinant virus is a recombinantMorbillivirus, preferably, a recombinant measles virus (MV).

19. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 18, wherein said recombinant MV is derived from MVstrain Edmonston A or B, preferably B, more preferably from MV vaccinestrain Schwarz/Moraten.

20. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 19, wherein the at least one expressible polynucleotideencoding an IL-12 polypeptide is comprised in a polynucleotide encodingthe recombinant virus of the family Paramyxoviridae.

21. The recombinant virus of the family Paramyxoviridae of any one ofembodiments 1 to 20, wherein said polynucleotide encoding therecombinant virus of the family Paramyxoviridae comprises the nucleicacid sequence of any one of SEQ ID Nos: 4 to 7, 14, and 15.

22. A polynucleotide encoding the recombinant virus of the familyParamyxoviridae according to any one of embodiments 1 to 21.

23. The polynucleotide according to embodiment 22, wherein saidpolynucleotide comprises the nucleic acid sequence any one of SEQ IDNos: 4 to 7, 14, and 15.

24. A host cell comprising the recombinant virus of the familyParamyxoviridae according to any one of embodiments 1 to 21 and/or thepolynucleotide encoding the recombinant virus of the familyParamyxoviridae according to embodiment 21 or 22.

25. A medicament comprising

-   -   (a) (i) a recombinant virus of the family Paramyxoviridae        comprising an expressible polynucleotide encoding an IL-12 and        not comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;        -   (ii) a recombinant virus of the family Paramyxoviridae            according of any one of embodiments 1 to 21,        -   (iii) a polynucleotide encoding the recombinant virus of the            family Paramyxoviridae of (i) and/or (ii),        -   (iv) a host cell comprising the recombinant virus of the            family Paramyxoviridae according to (i) or (ii) and/or a            polynucleotide encoding the recombinant virus of the family            Paramyxoviridae of (iii); or        -   (v) any combination of (i) to (iv); and    -   (b) at least one pharmacologically acceptable excipient.

26. A method for treating cancer in a subject afflicted with cancer,comprising

-   -   a) contacting said subject with        -   (i) a recombinant virus of the family Paramyxoviridae            comprising an expressible polynucleotide encoding an IL-12            and not comprising an expressible polynucleotide encoding a            CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a            CD86 antagonist, or a PD-L1 antagonist;        -   (ii) a recombinant virus of the family Paramyxoviridae            according of any one of embodiments 1 to 21,        -   (iii) a polynucleotide encoding the recombinant virus of the            family Paramyxoviridae of (i) and/or (ii),        -   (iv) a host cell comprising the recombinant virus of the            family Paramyxoviridae according to (i) or (ii) and/or a            polynucleotide encoding the recombinant virus of the family            Paramyxoviridae of (iii); or        -   (v) any combination of (i) to (iv); and, thereby,    -   b) treating cancer in a subject afflicted with cancer.

27. The method of embodiment 26, wherein said recombinant virus of thefamily Paramyxoviridae of (i) is a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 polypeptide and not comprising an expressible polynucleotideencoding a ligand for an immune checkpoint blockade protein.

28. The method of embodiment 26 or 27, wherein said recombinant virus ofthe family Paramyxoviridae of (i) is a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 polypeptide as the only expressible polynucleotide encoding anactivator of the immune response.

29. The method of any one of embodiments 26 to 28, wherein said canceris a solid cancer, a metastasis, or a relapse thereof.

30. The method of any one of embodiments 26 to 29, wherein treatingcancer is reducing tumor burden.

31. The method of any one of embodiments 26 to 30, wherein said canceris malignant melanoma, head and neck cancer, hepatocellular carcinoma,pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastriccarcinoma, colorectal carcinoma, lymphomas or leukemias.

32. An in vitro method for activating immune cells with antitumoractivity in a sample comprising cancer cells and immune cells,comprising

a) contacting said sample comprising cancer cells and immune cells with

-   -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae according        of any one of embodiments 1 to 21,    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae according to (i) or (ii) and/or a polynucleotide        encoding the recombinant virus of the family Paramyxoviridae of        (iii); or    -   (v) any combination of (i) to (iv); and thereby,

b) activating immune cells with antitumor activity comprised in saidsample.

33. Use of

-   -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae according        of any one of embodiments 1 to 21,    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae according to (i) or (ii) and/or a polynucleotide        encoding the recombinant virus of the family Paramyxoviridae of        (iii); or    -   (v) any combination of (i) to (iv);

for the manufacture of a medicament for treating cancer.

34. A recombinant virus of the family Paramyxoviridae according to anyone of embodiments 1 to 21 and/or a polynucleotide according toembodiment 22 or 23 for use in medical treatment.

35. A recombinant virus of the family Paramyxoviridae

(i) comprising an expressible polynucleotide encoding an IL-12 and notcomprising an expressible polynucleotide encoding a CTLA-4 antagonist, aPD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1antagonist; and/or

(ii) according of any one of embodiments 1 to 21,

for use in treatment of inappropriate cell proliferation.

36. The recombinant virus of the family Paramyxoviridae for use ofembodiment 35, wherein treatment of inappropriate cell proliferation iscancer treatment.

37. A kit comprising

-   -   (i) a recombinant virus of the family Paramyxoviridae comprising        an expressible polynucleotide encoding an IL-12 and not        comprising an expressible polynucleotide encoding a CTLA-4        antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86        antagonist, or a PD-L1 antagonist;    -   (ii) a recombinant virus of the family Paramyxoviridae according        of any one of embodiments 1 to 21,    -   (iii) a polynucleotide encoding the recombinant virus of the        family Paramyxoviridae of (i) and/or (ii),    -   (iv) a host cell comprising the recombinant virus of the family        Paramyxoviridae according to (i) or (ii) and/or a polynucleotide        encoding the recombinant virus of the family Paramyxoviridae of        (iii); or    -   (v) any combination of (i) to (iv);

housed in a container.

All references cited in this specification are herewith incorporated byreference with respect to their entire disclosure content and thedisclosure content specifically mentioned in this specification.

The following Examples shall merely illustrate the invention. They shallnot be construed, whatsoever, to limit the scope of the invention.

EXAMPLES Example 1 Cell Culture

Vero African green monkey kidney cells were obtained from the AmericanType Culture Collection (Manassas, VA). Vero-αHis cell line stablyexpressing a single chain antibody (38cab) against His₆tag (Nakamura etal. 2005) was a kind gift of S. J. Russel (Mayo Clinic, Rochester,Minn.). Murine colon adenocarcinoma cells MC38cea (transduced for stableexpression of human CEA antigen) and the parental MC38 cell line were agift of R. Cattaneo (Mayo Clinic, Rochester, Minn.). B16-CD20 havepreviously been generated by transducing the parental cell line with alentiviral vector encoding human CD20 (Engeland et al. 2014). All celllines were cultivated in either Dulbecco's modified Eagle's medium(DMEM; Life Technologies, Darmstadt, Germany) or Roswell Park MemorialInstitute 1640 medium (RPMI 1640; Life Technologies) supplemented with10% Fetal Calf Serum (FCS) at 37° C. in a humidified atmosphere with 5%CO₂ and routinely tested for mycoplasma contamination.

Example 2 Cloning of Recombinant MeVac Genomes

The cDNA plasmids encoding recombinant MeV genomes were constructed onthe basis of the commercially used Schwarz/Moraten vaccine strain(MeVac) (Combredet et al. 2003). Transgenes were inserted in additionaltranscription units (ATUs) containing additional gene-end gene-startsignals and a unique cloning site. Transgenes smaller than 1 kbpincluding murine GM-CSF (426 bp), murine IP-10 (312 bp) and eGFP (720bp) were inserted into the leader position of pcMeVac as Mlul-Asclfragments via the unique Ascl restriction site. The mGM-CSF and eGFPfragments were amplified from the MeV Edmonston B (Nse) vaccine straingenomes encoding the respective transgenes (Grossardt et al. 2013). ThemIP-10 (mCxcl10) gene was amplified with primers flanking the novelconstruct and adding a Mlul site and a Kozak sequence (GCCACC) in the5′-end and a two nucleotide TA spacer and Ascl site in the 3′-end usingcDNA obtained from murine splenocytes.

Cassette encoding a murine IL-12 fusion protein (FmIL-12) consisting ofmurine IL-12 p40 and p35 subunits linked by a (Gly₄Ser)₃ for insertioninto MeV genome had previously been constructed by C. Grossardt(Grossardt 2013) based on results of Lieschke and colleagues (Lieschkeet al. 1997). FmIL-12 construct (1650 bp) was excised from pCGexpression vector (constructed by C. Grossardt) as Paul-Mlul fragmentand inserted into the MeVac genome downstream the P ORF via the uniqueMauBl cloning site.

Antibodies against negative murine T cell regulators CTLA-4 and PD-L1 aswell as soluble form of murine CD80 T cell costimulatory molecule andhuman IgG1-Fc fragment for use as a control were inserted into the ATUdownstream the H gene. Cassettes encoding antibodies against murineCTLA-4 and PD-L1 and human IgG1-Fc fragment previously designed by C. E.Engeland (Engeland et al. 2014) were used as templates. The respectiveconstructs were excised from pCG expression vectors as Miul-Paulfragments and inserted into the pcMeVac H-ATU via the unique MauBlcloning site.

Murine CD80 molecule was inserted for expression from MeVac in a solubleform. CD80-Fc was constructed by fusing the extracellular part of themurine CD80 with the same human IgG1-Fc region as used in bothanti-CTLA-4 and anti-PD-L1 constructs via fusion PCR. The first PCRfragment consisting of the Mlul restriction site followed by Kozaksequence (GCCACC), murine CD80 signal peptide, extracellular part (up tothe asparagine in position 246) of murine CD80 and first 26 nucleotidesof the hinge of IgG1-Fc was synthesized using pCG vector encoding murineCD80 as a template. The second PCR fragment consisting of the humanIgG1-Fc region followed by myc tag, stop codon and Ascl restriction sitewas synthesized using pCG vector encoding human IgG1-Fc as a template.The obtained PCR products were fused with flanking primers in an overlapPCR obtaining the mCD80-Fc construct of 1614 bp. The mCD80-Fc wasinserted into the pcMeVac H-ATU as a Mlul-Ascl fragment via the uniqueMauBl cloning site.

MeVac genomes encoding the previously described transgenes with a fullyretargeted MeV H attachment gene were constructed to allow targetedtransduction of murine MC38cea and B16-CD20 cells. MeVac H gene wasexchanged for H gene with mutated attachment sites to the natural MeVreceptors CD46 and CD150, fused to a single chain antibody (39cab)against human CEA or CD20 and containing a C-terminal His₆tag. Theretargeting system allows a flexible change of the targeted antigen byexchanging the specific 39cab as a Sfil-Notl fragment.

Example 3 Virus Propagation and Titration

Recombinant MeVac particles were obtained from cDNA constructs accordingto Radecke et al. (Radecke et al. 1995) and propagated on Vero-αHiscells according to Nakamura et al. (Nakamura et al. 2005). Forpropagation Vero-αHis cells were infected at a multiplicity of infection(MOI) of 0.03 and cultivated at 37° C. 5% CO₂ until syncytia had spreadacross the whole cell layer (36-48 h post infection). Subsequentlyculture medium was completely removed, cells were scraped and collectedand viral particles released by one freeze-thaw cycle. Cellular debriswas removed by centrifugation at 6000×g for 5 min. The amount of viralparticles was determined by 1:10 serial dilution titrations inoctuplicates on 1.5×10⁴Vero-αHis cells per well in 96-well cell cultureplates. Individual syncytia were counted 72 h post infection and titerscalculated as cell infectious units per ml (ciu/ml).

Example 4 Statistical Analyses

Statistical analyses were performed using GraphPad Prism software(version 5.04; GraphPad Software, La Jolla, Calif.). Tumor volumes andELISA results in restimulation experiments were analysed by one-wayANOVA with Tukey's multiple comparison test. Survival curves wereanalyzed by log-rank (Mantel-Cox) test with Bonferroni-Holm correctionfor multiple comparisons. Result was considered statisticallysignificant if p value was lower than 0.05 after correcting for multiplecomparisons.

Example 5 Characterization of Virus Replication

Vero-αHis and MC38cea cells were seeded in 12-well plates (1×10⁵ cellsper well). After 12 h the cell culture medium was removed and cells wereinfected with the respective viruses at MOI=3 in 300 μl OptiMEM intriplicates for each time point and cultivated at 37° C. 5% CO₂. Afteradsorption for ca. 2 h the inoculum was removed and substituted with 1ml DMEM+10% FCS per well. Cells were scraped in the culture medium atthe designated time points, collected and snap frozen in liquidnitrogen. The amount of viral particles was determined by 1:10 serialdilution titrations in quadruplicates on 1.5×10⁴ Vero-αHis cells perwell in 96-well cell culture plates. Individual syncytia were counted 72h post infection and titers calculated as ciu/ml.

Example 6 Assessment of Virus Cytotoxic Potential In Vitro

MC38cea cells were seeded in 6-well plates (2×10⁵ cells per well). After12 h the cell culture medium was removed and cells were infected withthe respective viruses at MOI=5 in 800 μl OptiMEM in triplicates foreach time point and cultivated at 37° C. 5% CO₂. After adsorption forca. 2 h the inoculum was removed and substituted with 2 ml DMEM+10% FCSper well. At the designated time points cell viability was determinedusing Colorimetric Cell Viability Kit III (XTT) (PromoKine, Heidelberg,Germany) according to instructions of the manufacturer.

Example 7 Characterization of Transgene Expression

MC38cea cells were seeded in 12-well plates (1×10⁵ cells per well).After 12 h the cell culture medium was removed and cells were infectedwith the respective viruses at MOI=3 in 300 μl OptiMEM in triplicatesfor each time point and cultivated at 37° C. 5% CO₂. After adsorptionfor ca. 2 h 700 μl DMEM+10% FCS per well was added. Supernatants werecollected at the designated time points. Time point Oh was representedby inoculum in OptiMEM used for infection. Expression of the respectiveimmunomodulators was detected by ELISA. Commercially available ELISAkits were used for detection of mGM-CSF, FmIL-12, mIP-10 (R&D Systems,Wiesbaden, Germany) and CD80-Fc (Boster Biological Technology,Offenbach, Germany) according to instructions of the manufacturer.Anti-CTLA-4 and anti-PD-L1 were detected by binding to their respectivemurine proteins. Ninety-six well plates (Nunc Maxisorp, Thermo FisherScientific, Schwerte, Germany) were coated with 100 ng recombinantHis-tagged murine CTLA-4 or PD-L1 (Life Technologies). Wells wereblocked and 100 μl of the respective samples were added and incubatedfor 2 h. After washing the antibodies were detected with anti-humanIgG-Fc Biotin (clone HP-6071; Sigma-Aldrich, Taufkirchen, Germany),Peroxidase conjugated Streptavidin (Dianova, Hamburg, Germany) and1-Step Ultra-TMB ELISA Substrate Solution (Thermo Scientific, Karlsruhe,Germany). Absorbance was measured using Infinite M200 Pro microplatereader and i-control software (Tecan, Mannedorf, Switzerland).

Example 8 Flow Cytometry for Detection of anti-PD-L1 Binding to MC38ceaCells

Vero-αHis cells were seeded in 15 cm cell culture dishes and infectedwith MeVac encoding anti-PD-L1 or IgG1-Fc with MOI=0.03. Supernatantswere collected (15m1 per plate) when syncytia had spread over the wholecell layer (ca. 36 h post infection). 1×10⁶ MC38cea cells were incubatedwith anti-PD-L1 or IgG1-Fc containing supernatant previously collectedfrom one fully infected 15 cm dish for 1 h with rotation at room t^(o).After washing the bound anti-PD-L1 was detected by staining with anti-HA(clone HA-7; Sigma-Aldrich) and goat anti-mouse IgG PE (polyclonal; BDBiosciences, Heidelberg, Germany). The stained cells were resuspended inDPBS with 0.2 μg/ml DAPI (Sigma-Aldrich) and directly acquired on LSRIIflow cytometer (BD Biosciences) collecting at least 10000 events persample.

Example 9 Isolation of Murine Splenocytes

Spleens were aseptically isolated and maintained in RPMI 1640 (LifeTechnologies, Darmstadt, Germany) at 4° C. until further processing.Spleen was passed through a 100 μm nylon cell strainer (BD Biosciences,Heidelberg, Germany) into 10 ml RPMI 1640 and cells were pelleted at300×g for 5 min. For red blood cell lysis pellet was resuspended in 1 mlACK Lysing solution (Life Technologies), incubated 10 min at room t^(o)and centrifuged at 300×g for 5 min. Cells were resuspended in DPBS (LifeTechnologies) and cell concentration determined using Neubauerhemocytometer and Trypan blue (Sigma-Aldrich) staining for dead cellexclusion.

Example 10 Functional Assay for MeVac Encoded Anti-PD-L1, CD80-Fc andAnti-CTLA-4

Vero-αHis cells were seeded in 15 cm cell culture dishes and infectedwith MeVac encoding anti-PD-L1, anti-CTLA-4, CD80-Fc or IgG1-Fc withMOI=0.03. Supernatants were collected (15 ml per plate) when syncytiahad spread over the whole cell layer (ca. 36 h post infection). 2×10⁵MC38cea cells were incubated with 2 ml medium collected from theVero-αHis infected with the respective viruses for 5 min with rotationat room t^(o) and pelleted by centrifugation 5 min at 300×g. Theprocedure was repeated six times. The treated cells were resuspended in100 μl activation medium—RPMI 1640 supplemented with 5% FCS, 1%Penicillin-Streptomycin (Life Technologies), 500 μM ionomycin (CaymanChemical Company, Hamburg, Germany) and 5 μM PMA (Cayman ChemicalCompany) and seeded in 96-well plate. 2×10⁵ freshly isolated splenocytesfrom C57BL/6J mouse in 100 μl activation medium were added per each wellwith the treated MC38cea cells. Cells were cocultivated 24 h at 37° C.5% CO₂ and supernatants collected subsequently. IFN-γ concentration wasdetermined using mouse IFN gamma ELISA Ready-SET-Go!® (eBioscience,Frankfurt am Main, Germany) according to the instructions of themanufacturer.

Example 11 Functional Assay for MeVac Encoded FmIL-12

Vero-αHis cells were seeded in 15 cm cell culture dishes and infectedwith MeVac encoding FmIL-12 or eGFP. Supernatants were collected (15 mlper plate) when syncytia had spread over the whole cell layer (ca. 36 hpost infection). FmIL-12 concentration was assessed using Mouse IL-12p70 Quantikine ELISA Kit (R&D Systems). 2×10⁶ freshly isolatedsplenocytes from a C57BL/6J mouse were resuspended in RPMI 1640supplemented with 10% FCS, 1% Penicillin-Streptomycin solution and 50U/ml recombinant murine IL-2 (Miltenyi, Bergisch Gladbach, Germany) withvarying concentrations of MeVac encoded FmIL-12 or respective parts ofsupernatant from cells infected with eGFP encoding MeVac. Splenocyteswere seeded in 12-well plates and incubated 48 h at 37° C. 5% CO₂.Supernatants were collected and IFN-γ concentration assessed using mouseIFN gamma ELISA Ready-SET-Go!® (eBioscience) according to theinstructions of the manufacturer.

Example 12 Assessment of Therapeutic Efficacy In Vivo

MC38cea cells were subcutaneously (s.c.) implanted into six to eightweeks old C57BI/6J mice (Harlan Laboratories, Rossdorf Germany or DKFZ,Heidelberg, Germany). When average tumor volume reached 50-100 mm³(depending on experiment) treatment was initiated. Mice receivedintratumoral (i.t.) injections with the respective viruses on four orfive consecutive days with 5×10⁵ or 1×10⁶ ciu in 100 μl. Mice in themock group received treatment with 100 μl OptiMEM. Tumor volume wasdetermined every third day measuring largest and smallest diameter witha caliper and calculating the volume using a formula: largestdiameterx(smallest diameter)²×0.5. Mice were sacrificed when tumorvolume exceeded 1500 mm³, ulceration occurred or signs of severe illnesswere observed.

Example 13 Antigen Specific IFN-γ Memory Recall with Murine Splenocytes

MC38cea, MC38 and B16 cells were treated with 20 μg/ml mitomycin-C(Sigma-Aldrich) for 2 h with shaking at 37° C. After subsequent washingthree times with DPBS cells were resuspended in activation mediumcontaining RPMI 1640 supplemented with 10% FCS, 1%Penicillin-Streptomycin and 50 U/ml recombinant murine IL-2. Freshlyisolated murine splenocytes were resuspended in the same activationmedium. Cocultures were prepared in 24-well plates seeding 1×10⁵mitomycin-c treated tumor cells or 1×10⁶ ciu MeVac with 1×10⁶splenocytes per well in 0.5 ml total volume of activation medium. Ascontrols 1×10⁶ splenocytes were cocultivated also with Vero-αHis orDLD-1 cell lysates prepared by lysis of 1×10⁶cells per ml with onefreeze-thaw cycle. Cells were cocultivated for 48 h, supernatantscollected and IFN-y concentration assessed using mouse IFN gamma ELISAReady-SET-Go!® (eBioscience) according to the instructions of themanufacturer.

REFERENCES

-   Combredet, C. et al., 2003. A Molecularly Cloned Schwarz Strain of    Measles Virus Vaccine Induces Strong Immune Responses in Macaques    and Transgenic Mice A Molecularly Cloned Schwarz Strain of Measles    Virus Vaccine Induces Strong Immune Responses in Macaques and    Transgenic Mice.-   Engeland, C. E. et al., 2014. CTLA-4 and PD-L1 Checkpoint Blockade    Enhances Oncolytic Measles Virus Therapy. Molecular Therapy, 22(11),    pp. 1949-1959.-   Grossardt, C., 2013. Engineering Targeted and Cytokine-armed    Oncolytic Measles Viruses. Ruperto-Carola University of Heidelberg.-   Grossardt, C. et al., 2013. Granulocyte-Macrophage    Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an    Effective Therapeutic Cancer Vaccine. Human Gene Therapy, 24(7), pp.    644-654.-   Lieschke, G. J . et al., 1997. Bioactive murine and human    interleukin-12 fusion proteins which retain antitumor activity in    vivo. Nature biotechnology, 15(1), pp. 35-40.-   Nakamura, T. et al., 2005. Rescue and propagation of fully    retargeted oncolytic measles viruses. Nature biotechnology, 23(2),    pp. 209-14.-   Radecke, F. et al., 1995. Rescue of measles viruses from cloned DNA.    The EMBO journal, 14(23), pp. 5773-84. Available at:

1. A recombinant virus of the family Paramyxoviridae, comprising anexpressible polynucleotide encoding an IL-12 polypeptide, wherein saidIL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35subunit of an IL-12 and a p40 subunit of an IL-12.
 2. The recombinantvirus of the family Paramyxoviridae of claim 1, wherein said p35 subunitand said p40 subunit of said IL-12 fusion polypeptide are from the samespecies.
 3. The recombinant virus of the family Paramyxoviridae of claim1, wherein said IL-12 fusion polypeptide comprises the structurep35-linker-p40.
 4. The recombinant virus of the family Paramyxoviridaeof claim 1, wherein said linker is -(glycine₄-serine)_(n)-, with n=1 to10.
 5. The recombinant virus of the family Paramyxoviridae of claim 1,further comprising at least one expressible polynucleotide encoding afurther activator of the immune response.
 6. The recombinant virus ofthe family Paramyxoviridae of claim 5, wherein said further activator ofthe immune response is a secreted immunoglobulin.
 7. The recombinantvirus of the family Paramyxoviridae of claim 5, wherein said furtheractivator of the immune response is an Fc domain of an antibody.
 8. Therecombinant virus of the family Paramyxoviridae of claim 5, wherein saidfurther activator of the immune response is a secreted soluble activatorof the immune response.
 9. The recombinant virus of the familyParamyxoviridae of claim 5, wherein said further activator of the immuneresponse is a secreted soluble anti-PD-L1 antibody.
 10. The recombinantvirus of the family Paramyxoviridae of claim 1, wherein said recombinantvirus is a recombinant Morbillivirus.
 11. The recombinant virus of thefamily Paramyxoviridae of claim 1, wherein said recombinant virus isderived from a measles virus strain Edmonston A or B.
 12. Therecombinant virus of the family Paramyxoviridae of claim 1, wherein theat least one expressible polynucleotide encoding an IL-12 polypeptide iscomprised in a polynucleotide encoding the recombinant virus of thefamily Paramyxoviridae.
 13. The recombinant virus of the familyParamyxoviridae of claim 1, wherein said polynucleotide encoding therecombinant virus of the family Paramyxoviridae comprises the nucleicacid sequence of any one of SEQ ID NOs:4 to 7, 14, and
 15. 14. Amedicament comprising (a) (i) a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 and not comprising an expressible polynucleotide encoding a CTLA-4antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, ora PD-L1 antagonist; (ii) a recombinant virus of the familyParamyxoviridae according to claim 1, (iii) a polynucleotide encodingthe recombinant virus of the family Paramyxoviridae of (i) and/or (ii),(iv) a host cell comprising the recombinant virus of the familyParamyxoviridae according to (i) or (ii) and/or a polynucleotideencoding the recombinant virus of the family Paramyxoviridae of (iii);or (v) any combination of (i) to (iv); and (b) at least onepharmacologically acceptable excipient.
 15. A method for treating cancerin a subject afflicted with cancer, comprising a) contacting saidsubject with (i) a recombinant virus of the family Paramyxoviridaecomprising an expressible polynucleotide encoding an IL-12 and notcomprising an expressible polynucleotide encoding a CTLA-4 antagonist, aPD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1antagonist; (ii) a recombinant virus of the family Paramyxoviridaeaccording of claim 1, (iii) a polynucleotide encoding the recombinantvirus of the family Paramyxoviridae of (i) and/or (ii), (iv) a host cellcomprising the recombinant virus of the family Paramyxoviridae accordingto (i) or (ii) and/or a polynucleotide encoding the recombinant virus ofthe family Paramyxoviridae of (iii); or (v) any combination of (i) to(iv); and, thereby, b) treating cancer in a subject afflicted withcancer.
 16. The method of claim 15, wherein said recombinant virus ofthe family Paramyxoviridae of (i) is a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 polypeptide and not comprising an expressible polynucleotideencoding a ligand for an immune checkpoint blockade protein.
 17. Themethod of claim 15, wherein said recombinant virus of the familyParamyxoviridae of (i) is a recombinant virus of the familyParamyxoviridae comprising an expressible polynucleotide encoding anIL-12 polypeptide as the only expressible polynucleotide encoding anactivator of the immune response.
 18. The method of claim 15, whereinsaid cancer is a solid cancer, a metastasis, or a relapse thereof. 19.The method of claim 15, wherein treating cancer is reducing tumorburden.
 20. The method of claim 15, wherein said cancer is malignantmelanoma, head and neck cancer, hepatocellular carcinoma, pancreaticcarcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma,colorectal carcinoma, lymphomas or leukemias.
 21. The recombinant virusof the family Paramyxoviridae of claim 1, wherein said p35 subunit andsaid p40 subunit of said IL-12 fusion polypeptide are a mouse p35subunit and a mouse p40 subunit or a variant thereof, or a human p35subunit and a human p40 subunit or a variant thereof.